# Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

> **NCT02261714** · PHASE1,PHASE2 · COMPLETED · sponsor: **Targovax ASA** · enrollment: 32 (actual)

## Conditions studied

- Pancreatic Cancer, Resected

## Interventions

- **BIOLOGICAL:** TG01
- **BIOLOGICAL:** TG01

## Key facts

- **NCT ID:** NCT02261714
- **Lead sponsor:** Targovax ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02261714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02261714, "Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02261714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*